Výsledky vyhledávání - "P G, Giannessi"

Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma

Autor: Editta Baldini, Riccardo Rosso, Flavio Carnino, M. Venturini, S. Mammoliti, Alfredo J. Moyano M.D., Valentina Guarneri, Angelo Bolognesi, D. Aldrighetti, Massimo Costantini, Pierfranco Conte, P. G. Giannessi, Tiziana Prochilo, Barbara Salvadori, Paolo Bruzzi

Publikováno v: Cancer. 101:704-712

BACKGROUND The authors performed a randomized trial comprising patients with metastatic breast carcinoma (MBC). They used a noninferiority design to evaluate whether the results of sequential administration of epirubicin and paclitaxel were not marke

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09ec8754ec7fcc8f3af01119d057a157
https://doi.org/10.1002/cncr.20400

Zobrazit plný text záznamu

Accelerated versus standard cyclophosphamide, epirubicin and5-fluorouracil or cyclophosphamide, methotrexate and5-fluorouracil: a randomized phase III trial in locally advanced breast cancer

Autor: Franco Mosca, Paolo Bruzzi, Tiziana Prochilo, Editta Baldini, Manuela Roncella, Pierfranco Conte, G. Gardin, R. Lionetto, P. G. Giannessi, Paola Collecchi, R. Rosso, G Evangelista

Publikováno v: Annals of Oncology. 14:227-232

Background The purpose of this study was to evaluate the impact of a dose-dense primary chemotherapy on pathological response rate (pCR) in patients with locally advanced breast cancer (LABC) treated with combined modality therapy. Patients and metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c29ba8835a148bad9839b5907d83c02a
https://doi.org/10.1093/annonc/mdg069

Zobrazit plný text záznamu

Intraperitoneal Carboplatin with or without Interferon-α in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients

Publikováno v: Gynecologic Oncology. 65:499-505

From June 1990 to October 1994, 111 advanced ovarian cancer patients with minimal (less than 2 cm) residual disease after platinum-based front-line chemotherapy and second-look laparotomy entered a cooperative randomized study aimed at evaluating the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::87c9fc1df57374229e28f3b9ce8d4a98
https://doi.org/10.1006/gyno.1997.4689

Zobrazit plný text záznamu

Ovarian cancer in elderly women

Autor: Pf Conte, Antonella Romanini, P. G. Giannessi, Angiolo Gadducci, Antonio Fanucchi, Isa Brunetti

Publikováno v: International Journal of Gynecological Cancer. 7:23-26

The incidence of ovarian cancer is > 50% in women aged 65 years. Histology and stage at diagnosis are both related to age, which appears to be an independent prognostic factor for survival in univariate analysis. Special conditions relating to the tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bcc4929ebf53c0ab5cc1d488fdd22ff8
https://doi.org/10.1046/j.1525-1438.7.s1.2.x

Zobrazit plný text záznamu

Accelerated Epirubicin-Ifosfamide-Dacarbazine Regimen in Patients with Adult Soft Tissue Sarcomas

Autor: Andrea Michelotti, Carmelo Bengala, P. G. Giannessi, Antonella Romanini, Pierfranco Conte

Publikováno v: American Journal of Clinical Oncology. 19:78-81

Background Neutropenia and infections are the dose-limiting toxicities of the EID regimen and can cause dose reduction and/or delay in chemotherapy administration. The purpose of this study was to verify if EID + G-CSF is feasible with an acceptable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c593e305e4511fe216ce4874c9604292
https://doi.org/10.1097/00000421-199602000-00016

Zobrazit plný text záznamu

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety

Autor: Pierfranco Conte, P. G. Giannessi, A Bolognesi, Editta Baldini, Tiziana Prochilo, Barbara Salvadori, M. Venturini, Paolo Bruzzi, Cinzia Orlandini, D. Aldrighetti, L. Gallo, R. Rosso, Flavio Carnino

Publikováno v: British Journal of Cancer

The aim of the study was to evaluate cardiac safety of two different schedules of Epirubicin and Paclitaxel in advanced breast cancer patients enrolled into a multicenter randomized phase III trial. Patients received Epirubicin 90 mg m(-2) plus Pacli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38f822f5892138b48841d3df8541f050
https://hdl.handle.net/11380/306075

Zobrazit plný text záznamu

Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumor proliferative activity, BCL-2 expression and relationship between tumor regression and biological markers

Autor: Editta Baldini, Generoso Bevilacqua, Manuela Roncella, G. Gardin, A Passoni, G Evangelista, Paola Collecchi, Pf Conte, P. G. Giannessi, Antonio Giuseppe Naccarato

The rate of tumour cell proliferation evaluated by the [ 3 H]-thymidine labelling index ([ 3 H]-dT-LI) is known to be an independent prognostic factor in patients with operable breast cancer and significantly predicts the response to chemotherapy in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d760f24ce01a4de9bd628a4bffb75dd8
https://hdl.handle.net/11380/450136

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání